Keryx-AEterna colon cancer drug doesn't extend survival in trial

04/2/2012 | Wall Street Journal, The

Keryx Biopharmaceuticals and AEterna Zentaris' experimental drug perifosine, in combination with chemotherapy drug capecitabine, failed to improve the overall survival rate in patients with treatment-resistant advanced colorectal cancer compared with capecitabine alone, a late-stage trial showed. The partners are assessing whether to continue a late-stage trial evaluating perifosine for multiple myeloma.

View Full Article in:

Wall Street Journal, The

Published in Brief: